# Kuwait Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Kuwait HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Kuwait (KWT)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $281.7M
- Products: 25
- Buyer markets: 19
- Average CAGR: +6.3%
- Global sector size: $406.2B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $238.3B | $2.5K | $86.5B | -4.6% | 13 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $26.1B | $3.8M | $16.9B | +19.0% | 9 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $16.0B | $6.9 | $11.1B | -2.0% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $19.3B | $22.0K | $11.0B | +9.4% | 5 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $15.3K | $8.0B | -1.6% | 4 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $17.0B | $23.3K | $7.3B | +12.8% | 4 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $83.7M | $6.1B | -5.4% | 1 | +1.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $9.1B | $1.1K | $4.7B | +57.3% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $5.8B | $5.8 | $4.6B | -19.4% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $911.6K | $4.1B | +12.7% | 2 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $5.1M | $3.5B | -7.8% | 1 | +0.2% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $8.0B | $9.8 | $2.9B | -61.8% | 1 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $4.8B | $5.3K | $2.8B | +36.4% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $180.7 | $2.2B | -18.9% | 2 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $11.2 | $2.0B | +9.7% | 1 | +0.0% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $180.2M | $2.0B | +14.5% | 1 | +5.6% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.9B | $127.1 | $1.5B | -36.5% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $9.2K | $1.4B | +37.0% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $1.5K | $1.4B | +11.4% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $241.5 | $1.4B | -16.0% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $877.7 | $1.1B | +2.7% | 1 | +0.0% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $1.2B | $557.6K | $1.1B | -10.4% | 1 | +0.1% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $2.4K | $1.0B | +26.4% | 1 | +0.0% |
| HS 310210 - Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | $2.0B | $7.0M | $1.0B | -4.7% | 1 | +0.3% |
| HS 320611 - Colouring matter: pigments and preparations based on titanium dioxide, containing 80% or more by weight of titanium dioxide calculated on the dry matter | $1.1B | $293.8K | $996.0M | +100.8% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $48.2B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $33.3B calculated opportunity across 3 products.
- China (CHN): $21.3B calculated opportunity across 6 products.
- Germany (DEU): $21.0B calculated opportunity across 8 products.
- Netherlands (NLD): $10.5B calculated opportunity across 4 products.
- Canada (CAN): $8.6B calculated opportunity across 5 products.
- Belgium (BEL): $8.2B calculated opportunity across 2 products.
- United Kingdom (GBR): $8.1B calculated opportunity across 3 products.
- France (FRA): $5.0B calculated opportunity across 3 products.
- Italy (ITA): $4.9B calculated opportunity across 1 products.
- Ireland (IRL): $3.2B calculated opportunity across 1 products.
- India (IND): $3.1B calculated opportunity across 3 products.

## Growth stars

- HS 320611: +100.8% average CAGR, $996.0M calculated opportunity.
- HS 300212: +57.3% average CAGR, $4.7B calculated opportunity.
- HS 300670: +37.0% average CAGR, $1.4B calculated opportunity.
- HS 382600: +36.4% average CAGR, $2.8B calculated opportunity.
- HS 300290: +26.4% average CAGR, $1.0B calculated opportunity.
- HS 382499: +19.0% average CAGR, $16.9B calculated opportunity.
- HS 290531: +14.5% average CAGR, $2.0B calculated opportunity.
- HS 382200: +12.8% average CAGR, $7.3B calculated opportunity.
- HS 330300: +12.7% average CAGR, $4.1B calculated opportunity.
- HS 284410: +11.4% average CAGR, $1.4B calculated opportunity.

## Diversification opportunities

- HS 300490: 13 buyer markets, $86.5B calculated opportunity.
- HS 382499: 9 buyer markets, $16.9B calculated opportunity.
- HS 300439: 5 buyer markets, $11.0B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 382200: 4 buyer markets, $7.3B calculated opportunity.
- HS 300220: 3 buyer markets, $11.1B calculated opportunity.
- HS 300212: 2 buyer markets, $4.7B calculated opportunity.
- HS 330300: 2 buyer markets, $4.1B calculated opportunity.
- HS 300390: 2 buyer markets, $2.2B calculated opportunity.
- HS 290243: 1 buyer markets, $6.1B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.